Bolt Biotherapeutics to Participate in Upcoming September Conferences
Bolt Biotherapeutics (BOLT), a clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapies, has announced its participation in two major conferences this September. The company will be featured in:
1. A fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on September 6, 2024, at 7:00 a.m. EDT.
2. A company presentation at the H.C. Wainwright 26th Annual Global Investment Conference, available from September 9, 2024, at 7:00 a.m. EDT.
Both presentations will be accessible via webcast on Bolt's website, with replays available for 30 days after each event. This participation demonstrates Bolt's commitment to engaging with investors and showcasing its progress in the competitive field of cancer immunotherapy.
Bolt Biotherapeutics (BOLT), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di nuove immunoterapie per il cancro, ha annunciato la sua partecipazione a due importanti conferenze questo settembre. L'azienda sarà presente in:
1. Una chiacchierata informale alla 22ª Conferenza Annuale Globale sulla Salute di Morgan Stanley il 6 settembre 2024, alle 7:00 EDT.
2. Una presentazione dell'azienda alla 26ª Conferenza Annuale Globale sugli Investimenti di H.C. Wainwright, disponibile dal 9 settembre 2024, alle 7:00 EDT.
Entrambe le presentazioni saranno accesibili tramite webcast sul sito di Bolt, con repliche disponibili per 30 giorni dopo ciascun evento. Questa partecipazione dimostra l'impegno di Bolt nel coinvolgere gli investitori e mostrare i propri progressi nel competitivo settore delle immunoterapie per il cancro.
Bolt Biotherapeutics (BOLT), una empresa biofarmacéutica en etapa clínica centrada en el desarrollo de nuevas inmunoterapias contra el cáncer, ha anunciado su participación en dos conferencias importantes este septiembre. La empresa estará presente en:
1. Una charla informal en la 22ª Conferencia Anual Global de Salud de Morgan Stanley el 6 de septiembre de 2024, a las 7:00 a.m. EDT.
2. Una presentación de la empresa en la 26ª Conferencia Anual Global de Inversión de H.C. Wainwright, disponible a partir del 9 de septiembre de 2024, a las 7:00 a.m. EDT.
Ambas presentaciones estarán accesibles a través de un webcast en el sitio web de Bolt, con repeticiones disponibles durante 30 días después de cada evento. Esta participación demuestra el compromiso de Bolt de interactuar con los inversores y mostrar su progreso en el competitivo campo de la inmunoterapia contra el cáncer.
Bolt Biotherapeutics (BOLT), 혁신적인 암 면역 치료제를 개발하는 클리닉 단계의 생명공학 회사가 이번 9월 두 개의 주요 컨퍼런스에 참여한다고 발표했습니다. 회사는 다음과 같은 행사에 참석합니다:
1. 모건 스탠리 제22회 연례 글로벌 헬스케어 컨퍼런스의 파이어사이드 채팅이 2024년 9월 6일 오전 7시 EDT에 진행됩니다.
2. H.C. 웨인라이트 제26회 연례 글로벌 투자 컨퍼런스에서 회사 프레젠테이션이 2024년 9월 9일 오전 7시 EDT부터 제공됩니다.
두 프레젠테이션 모두 Bolt의 웹사이트를 통해 웹캐스트로 제공되며, 각 이벤트 후 30일 동안 다시보기 가능합니다. 이러한 참여는 투자자와의 소통 및 암 면역 치료 분야의 경쟁에서의 진전을 보여주려는 Bolt의 의지를 보여 줍니다.
Bolt Biotherapeutics (BOLT), une entreprise biopharmaceutique en phase clinique axée sur le développement de nouvelles immunothérapies contre le cancer, a annoncé sa participation à deux grandes conférences en septembre. L'entreprise sera présente à :
1. Une discussion informelle lors de la 22e Conférence Annuelle Mondiale sur la Santé de Morgan Stanley le 6 septembre 2024 à 7h00 EDT.
2. Une présentation de l'entreprise lors de la 26e Conférence Annuelle Mondiale sur l'Investissement de H.C. Wainwright, disponible à partir du 9 septembre 2024 à 7h00 EDT.
Les deux présentations seront accessibles via un webinaire sur le site de Bolt, avec des rediffusions disponibles pendant 30 jours après chaque événement. Cette participation démontre l'engagement de Bolt à interagir avec les investisseurs et à mettre en valeur ses progrès dans le domaine compétitif de l'immunothérapie contre le cancer.
Bolt Biotherapeutics (BOLT), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger Krebsimmuntherapien spezialisiert hat, hat seine Teilnahme an zwei großen Konferenzen im September angekündigt. Das Unternehmen wird vertreten sein bei:
1. Einem Kamin-Gespräch auf der 22. jährlichen globalen Gesundheitskonferenz von Morgan Stanley am 6. September 2024 um 7:00 Uhr EDT.
2. Einer Unternehmenspräsentation bei der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright, die ab dem 9. September 2024 um 7:00 Uhr EDT verfügbar sein wird.
Beide Präsentationen werden über einen Webcast auf der Website von Bolt zugänglich sein, mit Aufzeichnungen, die 30 Tage nach jeder Veranstaltung verfügbar sind. Diese Teilnahme zeigt Bolts Engagement, mit Investoren in Kontakt zu treten und seine Fortschritte im wettbewerbsintensiven Bereich der Krebsimmuntherapie zu präsentieren.
- None.
- None.
REDWOOD CITY, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in September:
- Morgan Stanley 22nd Annual Global Healthcare Conference
Fireside chat on Friday, Sept. 6, at 7:00 a.m. EDT (4:00 a.m. PDT) - H.C. Wainwright 26th Annual Global Investment Conference
Company presentation available on Monday, Sept. 9, at 7:00am EDT (4:00 a.m. PDT)
A webcast of the presentations will be available on the Events and Presentations page of Bolt’s website at www.boltbio.com. Archived replays will be available for 30 days following the event.
About Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Bolt Biotherapeutics’ pipeline candidates are built on the Company’s deep expertise in myeloid biology and cancer drug development. The Company’s pipeline includes BDC-3042, a first-in-class agonist antibody that activates macrophages by targeting Dectin-2, and BDC-4182, a next-generation Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is currently in a Phase 1 dose escalation trial that includes patients with any of seven different solid tumor types. BDC-4182 is supported by strong in vitro and in vivo data demonstrating potent anti-tumor activity, and activities are underway to support the initiation of clinical trials in 2025. Bolt Biotherapeutics is also developing additional Boltbody™ ISACs in strategic collaborations with leading biopharmaceutical companies. For more information, please visit https://www.boltbio.com/.
Investor Relations and Media Contact:
Matthew DeYoung
Argot Partners
(212) 600-1902
boltbio@argotpartners.com
FAQ
When is Bolt Biotherapeutics (BOLT) participating in the Morgan Stanley Global Healthcare Conference?
What conference is BOLT presenting at on September 9, 2024?
How can investors access Bolt Biotherapeutics' (BOLT) conference presentations?
What type of company is Bolt Biotherapeutics (BOLT)?
